BGLAP and plasma cell myeloma: A recent study of ibandronate in multiple myeloma (Menssen et al, 2002) demonstrated that patients experienced significantly fewer skeletal-related events per patient year when the ibandronate dose selected effectively suppressed the bone turnover markers serum osteocalcin and urinary Ctx.